Next Article in Journal
Modulation of Temoporfin Distribution in Blood by β-Cyclodextrin Nanoshuttles
Previous Article in Journal
Lyophilization Preserves the Intrinsic Cardioprotective Activity of Bioinspired Cell-Derived Nanovesicles
Review

Glioblastoma Multiforme—A Look at the Past and a Glance at the Future

1
Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2
Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Eun Seong Lee
Pharmaceutics 2021, 13(7), 1053; https://doi.org/10.3390/pharmaceutics13071053
Received: 6 June 2021 / Revised: 29 June 2021 / Accepted: 5 July 2021 / Published: 9 July 2021
Gliomas are the most common type of brain tumor that occur in adults and children. Glioblastoma multiforme (GBM) is the most common, aggressive form of brain cancer in adults and is universally fatal. The current standard-of-care options for GBM include surgical resection, radiotherapy, and concomitant and/or adjuvant chemotherapy. One of the major challenges that impedes success of chemotherapy is the presence of the blood–brain barrier (BBB). Because of the tightly regulated BBB, immune surveillance in the central nervous system (CNS) is poor, contributing to unregulated glioma cell growth. This review gives a comprehensive overview of the latest advances in treatment of GBM with emphasis on the significant advances in immunotherapy and novel therapeutic delivery strategies to enhance treatment for GBM. View Full-Text
Keywords: glioblastoma; blood–brain barrier (BBB); blood–brain tumor barrier (BBTB); surgery; radiation; chemotherapy; immune checkpoint inhibitors (ICIs); stem cell-based therapy; stem cell engineering; hydrogels; smart hydrogels; focused ultrasound (FUS) glioblastoma; blood–brain barrier (BBB); blood–brain tumor barrier (BBTB); surgery; radiation; chemotherapy; immune checkpoint inhibitors (ICIs); stem cell-based therapy; stem cell engineering; hydrogels; smart hydrogels; focused ultrasound (FUS)
Show Figures

Graphical abstract

MDPI and ACS Style

King, J.L.; Benhabbour, S.R. Glioblastoma Multiforme—A Look at the Past and a Glance at the Future. Pharmaceutics 2021, 13, 1053. https://doi.org/10.3390/pharmaceutics13071053

AMA Style

King JL, Benhabbour SR. Glioblastoma Multiforme—A Look at the Past and a Glance at the Future. Pharmaceutics. 2021; 13(7):1053. https://doi.org/10.3390/pharmaceutics13071053

Chicago/Turabian Style

King, Jasmine L., and Soumya R. Benhabbour 2021. "Glioblastoma Multiforme—A Look at the Past and a Glance at the Future" Pharmaceutics 13, no. 7: 1053. https://doi.org/10.3390/pharmaceutics13071053

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop